The importance of identifying EGFR mutations
EGFR mutations as biomarkers for targeted therapy
Since EGFR was discovered in 1978, our knowledge of its activating mutations and signaling pathways for cancer cell growth, proliferation and survival has continued to expand.1–3
The use of activating EGFR mutations as biomarkers has revolutionized the development of targeted TKI therapies to improve tumor response and patient outcomes in advanced NSCLC.2,3
In the era of precision medicine, determining the most effective NSCLC treatment strategy depends on the detection of EGFR mutations.2,3
EGFR sensitizing mutations have emerged as significant predictive and prognostic biomarkers for the selection of first-line TKI therapy and beyond2,3
LEARN ABOUT TESTING GUIDELINES
EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer; TKI: tyrosine kinase inhibitor.
1. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.
2. Tan CS, et al. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16:e447–59.
3. Yoneda K, et al. Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41:153–63.